The Board of Directors of Sunshine Biopharma, Inc. has authorized a buyback plan on January 19, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.361 USD | +3.56% |
|
+5.25% | -98.67% |
May. 21 | Earnings Flash (SBFM) SUNSHINE BIOPHARMA Posts Q1 Revenue $7.5M | MT |
May. 20 | Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-98.67% | 7.98M | |
+62.66% | 841B | |
+40.42% | 625B | |
-4.37% | 360B | |
+17.16% | 327B | |
+9.87% | 300B | |
+15.66% | 242B | |
+17.90% | 227B | |
+14.86% | 174B | |
+0.45% | 162B |
- Stock Market
- Equities
- SBFM Stock
- News Sunshine Biopharma, Inc.
- Sunshine Biopharma, Inc. authorizes a Buyback Plan.